Stewart D J, Evans W K, Logan D
Ontario Cancer Treatment and Research Foundation, Ottawa Regional Cancer Centre, Canada.
Am J Clin Oncol. 1994 Aug;17(4):313-6. doi: 10.1097/00000421-199408000-00006.
Eight evaluable patients with cisplatin-resistant non-small cell lung cancer (6 patients), small cell lung cancer (1 patient), or both breast and ovarian cancer (1 patient) were entered on a study to determine whether the addition of nifedipine plus pentoxifylline to cisplatin-based chemotherapy would result in increased chemotherapy efficacy. No patient responded to treatment. Myelosuppression may have been augmented by the nifedipine and pentoxifylline (median granulocyte nadir, 0.3 x 10(9)/L). Two patients developed febrile neutropenia. Nifedipine and pentoxifylline had to be stopped in two evaluable patients due to hypotension, and three additional inevaluable patients withdrew from the study due to nifedipine-pentoxifylline toxicity before receiving their chemotherapy. There was no indication that other types of chemotherapy toxicity were increased by the addition of nifedipine and pentoxifylline. A major problem with the strategy followed in this protocol was that patients whose tumors had failed to respond to cisplatin-based regimens were often too ill to tolerate additional cisplatin, particularly when accompanied by nifedipine-associated hypotension.
八名可评估的顺铂耐药非小细胞肺癌患者（6例）、小细胞肺癌患者（1例）或同时患有乳腺癌和卵巢癌的患者（1例）参与了一项研究，以确定在基于顺铂的化疗中添加硝苯地平和己酮可可碱是否会提高化疗疗效。没有患者对治疗有反应。硝苯地平和己酮可可碱可能增强了骨髓抑制（粒细胞最低点中位数为0.3×10⁹/L）。两名患者出现发热性中性粒细胞减少。两名可评估患者因低血压不得不停用硝苯地平和己酮可可碱，另外三名不可评估患者在接受化疗前因硝苯地平 - 己酮可可碱毒性退出研究。没有迹象表明添加硝苯地平和己酮可可碱会增加其他类型的化疗毒性。该方案所采用策略的一个主要问题是，其肿瘤对基于顺铂的方案无反应的患者通常病情太重，无法耐受额外的顺铂，尤其是当伴有硝苯地平相关的低血压时。
